1. Home
  2. VYGR vs NBTX Comparison

VYGR vs NBTX Comparison

Compare VYGR & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • NBTX
  • Stock Information
  • Founded
  • VYGR 2013
  • NBTX 2003
  • Country
  • VYGR United States
  • NBTX France
  • Employees
  • VYGR N/A
  • NBTX N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • NBTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VYGR Health Care
  • NBTX Health Care
  • Exchange
  • VYGR Nasdaq
  • NBTX Nasdaq
  • Market Cap
  • VYGR 235.4M
  • NBTX 201.9M
  • IPO Year
  • VYGR 2015
  • NBTX 2020
  • Fundamental
  • Price
  • VYGR $4.22
  • NBTX $3.75
  • Analyst Decision
  • VYGR Strong Buy
  • NBTX Strong Buy
  • Analyst Count
  • VYGR 9
  • NBTX 1
  • Target Price
  • VYGR $15.53
  • NBTX $12.00
  • AVG Volume (30 Days)
  • VYGR 374.5K
  • NBTX 8.7K
  • Earning Date
  • VYGR 03-03-2025
  • NBTX 09-18-2024
  • Dividend Yield
  • VYGR N/A
  • NBTX N/A
  • EPS Growth
  • VYGR N/A
  • NBTX N/A
  • EPS
  • VYGR 0.47
  • NBTX N/A
  • Revenue
  • VYGR $163,784,000.00
  • NBTX $45,220,186.00
  • Revenue This Year
  • VYGR N/A
  • NBTX N/A
  • Revenue Next Year
  • VYGR N/A
  • NBTX N/A
  • P/E Ratio
  • VYGR $9.13
  • NBTX N/A
  • Revenue Growth
  • VYGR 3.40
  • NBTX 526.17
  • 52 Week Low
  • VYGR $4.00
  • NBTX $2.76
  • 52 Week High
  • VYGR $10.66
  • NBTX $7.51
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 29.98
  • NBTX 53.25
  • Support Level
  • VYGR $4.20
  • NBTX $3.60
  • Resistance Level
  • VYGR $4.60
  • NBTX $3.95
  • Average True Range (ATR)
  • VYGR 0.31
  • NBTX 0.19
  • MACD
  • VYGR -0.08
  • NBTX -0.01
  • Stochastic Oscillator
  • VYGR 12.36
  • NBTX 38.18

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: